TREATMENT OF PATIENTS WITH HYPONATREMIA AND CARDIAC DISEASE

摘要

Compositions are directed to biased ligands which modulate V_1AR-G protein signaling and simultaneously activating GRK2/beta-arrestin-dependent signaling. Other compositions comprise agents which modulate expression or activity of an arginine vasopressin receptor (AVP-R) molecule. The biased ligands and agents may be contained in pharmaceutical compositions for administration to patients, for example, patients with heart failure and/or elevated levels of arginine vasopressin. We describe methods of treatment which may include administration of the compositions, alone or in combination with other treatments. Methods of identifying candidate therapeutic agents are also provided.